# North America Bedsores Pressure sores Market

> North America Bedsores or Pressure Sores Market Research Report Information by Diagnosis (Blood Tests and Others), by Treatment Type (Medications, Device Types, and Others), and by End-User (Hospitals and Clinics, Diagnostic Centers, and Others) – Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 19.1%
- **2024:** $ 9.5 Billion
- **2025:** $ 11.31 Billion
- **2035:** $ 65 Billion
- **Key Players:** IQVIA (US), Cerner Corporation (US), Optum (US), McKesson Corporation (US), Roche Diagnostics (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Philips Healthcare (NL)

**Report ID:** MRFR/MED/0263-HCR · **Pages:** 114 · **Author:** Nidhi Mandole & Kinjoll Dey · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/north-america-bedsores-pressure-sores-market-734

---

## Market Summary

## **North America Bedsores or Pressure Sores Market Overview**

North America Bedsores or Pressure sores Market Size was valued at USD 2.60 Billion in 2023. The North America Bedsores or Pressure sores industry is projected to grow from USD 2.74 Billion in 2024 to USD 4.85 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.99% during the forecast period (2024 - 2032). Bedsores are also known as pressure ulcers, pressure sores, or decubitus ulcers and are mostly found in the aged people and people who spend excessive time on the bed.

Bedsores or pressure sores can be prevented and avoids by the support surface devices which mainly includes mattresses, cushions, special overlays, and beds. 

Bedsores regularly create on skin that spreads bony areas of the body, for example, the heels, lower legs or ankles, hips, and tailbone. Individuals most at danger of bedsores are those with a medical or restorative condition that restricts their capacity to change positions, obliges them to utilize a wheelchair or limits them to a bed for quite a while. Expanding a large aged population and developing a focus on bedsores or pressure sores are the major driving factors that have increased the growth of the North American pressure ulcer device market.

Low-tech device portion represented the huge share in the North America pressure relief devices market. The strength of this market segment is significant because of prevention and avoidance of ulcer and cost adequacy. Foam-based sleeping pad, air-filled mattress, and gel-filled mattress, among certain others, are the low-tech devices commercially available in the market. Additionally, the increasing geriatric population all around also highlights the interest in pressure relief devices.

But, technical or specialized complexity, a prerequisite of talented staff and the high cost of the gadgets are some of the elements confining the interest of pressure relief devices to some degree amid the estimated time frame. The growth factor of this market was upheld by a rising inclination among large patients for gel-filled sleeping pads, as usage of these beddings empowers simple repositioning on the bed.

## **North America Bedsores or Pressure Sores Market Segment Insights**

The North American bedsores or pressure sores market is segmented on the basis of diagnosis, treatment type, and end-user.  North America bedsores or pressure sores market by diagnosis is segmented into blood test and others.

### **North America Bedsores or Pressure Sores Treatment Type Insights**

Based on the treatment type the market is segmented into medication and device type. Medication is segmented into Nonsteroidal anti-inflammatory drugs and topical pain medication. Nonsteroidal anti-inflammatory drugs are further segmented into ibuprofen (Advil, Motrin IB, others), naproxen sodium (Aleve), and others. Device type is further segmented into the low-tech device and hi-tech device. Low-tech devices are further segmented into foam based mattress, air-filled mattress, gel-filled mattress, and others.

### **North America Bedsores or Pressure Sores Diagnosis Insights**

On the basis of Diagnosis, Hi-Tech Device is further segmented into kinetic bed, dynamic air therapy bed, and others.

### **North America Bedsores or Pressure Sores End User Insights**

On the basis of end-user, the market is categorized into hospitals and clinics, diagnostic centers, and others.

**Key players**

Some of the key players in the North America bedsores or pressure sores market are ArjoHuntleigh, AB, Covidien PLC, Hill-Rom Holdings, Inc, Invacare Corporation, Stryker Corporation, Talley Group Limited, Paramount Bed Holdings Co., Ltd. and among others.

### **North America Bedsores or Pressure Sores Regional Insights**

North America bedsores or pressure sores market is segmented on the basis of geographies or regions which mainly includes the US and Canada. North America dominated the market for bedsores or pressure sores with more than 40% share of the total market in 2016. Increasing awareness of bedsores or pressure sores with technically advanced products, rising interest for different propelled mattress influence the growth of the market in North America. For example; according to the Agency for Healthcare Research and Quality (AHRQ), around 2.5 million people in the US are determined to have Bedsores or Pressure Sores.

There has been increasing health care spending in the United States. As a result of the succeeding increased health care utilization, medical management of pressure ulcers costs the United States health care system USD 9.1 billion to $11.6 billion per year. Out of all the US spending on healthcare, pressure ulcer accounts for about 2% of the total cost of Medicare being the largest payer for all adult hospitalizations due to a pressure ulcer. The cost of pressure ulcer care is likely to increase exponentially as life expectancy increases in the future

Moreover, there has been increasing patients suffering from pressure ulcer in the United States. Patients visiting the hospital to pressure ulcer are 75% higher than admissions for any other medical conditions and the significances of pressure ulcer development in hospitalized patients are particularly dire.  According to the survey conducted by Hill-Rom, a national and international survey of 104,485 patients, the overall hospital-acquired pressure ulcer (HAPU) rate was reported at 3.8%.

However, higher rates of hospital-acquired pressure ulcer (HAPU) were found in patients in Spinal Cord Units with 10.7%, Critical Care Units with 8.6%, Burn Units and Respiratory/Pulmonary units with 7.3% & 7.2% respectively.

**Research Methodology**

Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.

Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.

Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the North American Bedsores or Pressure Sores market. It was also used to obtain key information about major players, [market classification](../../../reports/data-classification-market-7378), and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, international organization of chemical manufacturers, some paid databases, and many others.

**Intended Audience**

## **North America Bedsores or Pressure Sores Market Segmentation**

### **North America Bedsores or Pressure Sores Diagnosis Outlook**

### **North America Bedsores or Pressure Sores Treatment Type Outlook**

### **North America Bedsores or Pressure Sores End-User Outlook**

### **North America Bedsores or Pressure Sores Regional Outlook**

**North America Bedsores or Pressure Sores Market by Key Players**

## Market Drivers

### Increased Investment in R&D

The surge in research and development (R&D) investments is a significant driver for the commercial pharmaceutical-analytics market. Pharmaceutical companies are allocating substantial budgets to R&D, with an average increase of 8% annually in North America. This investment is aimed at discovering new drugs and therapies, necessitating sophisticated analytics to interpret complex data sets. The commercial pharmaceutical-analytics market plays a crucial role in supporting these R&D efforts by providing tools that analyze clinical trial data and optimize drug development processes. As R&D spending continues to rise, the demand for analytics solutions is expected to follow suit.

### Rising Demand for Personalized Medicine

The increasing emphasis on personalized medicine is a pivotal driver for the commercial pharmaceutical-analytics market. As healthcare shifts towards tailored treatments, pharmaceutical companies are leveraging analytics to understand patient data better. This trend is evidenced by a projected growth rate of 12% in the personalized medicine sector, which directly influences the demand for [advanced analytics](https://www.marketresearchfuture.com/reports/advanced-analytics-market-5285) solutions. By utilizing data analytics, companies can identify patient-specific responses to therapies, thereby enhancing treatment efficacy. The commercial pharmaceutical-analytics market is thus positioned to benefit significantly from this shift, as analytics tools become essential for developing targeted therapies and improving patient outcomes.

### Emergence of Value-Based Healthcare Models

The shift towards value-based healthcare models is reshaping the commercial pharmaceutical-analytics market. As healthcare providers focus on patient outcomes rather than service volume, there is a growing need for analytics to measure the effectiveness of treatments. This transition is supported by a projected increase of 15% in the adoption of value-based care models in North America. Consequently, pharmaceutical companies are investing in analytics to demonstrate the value of their products. The commercial pharmaceutical-analytics market is likely to benefit from this trend, as analytics tools become essential for evaluating treatment outcomes and justifying healthcare expenditures.

### Growing Regulatory Compliance Requirements

The evolving landscape of regulatory compliance is a critical driver for the commercial pharmaceutical-analytics market. Regulatory bodies in North America are increasingly mandating the use of analytics to ensure drug safety and efficacy. Companies must comply with stringent regulations, which often require detailed data analysis and reporting. This trend is reflected in the fact that 70% of pharmaceutical companies report increased spending on compliance-related analytics. The commercial pharmaceutical-analytics market is thus positioned to thrive as organizations seek to enhance their compliance capabilities through advanced analytics solutions.

### Advancements in Data Management Technologies

Technological advancements in data management are transforming the commercial pharmaceutical-analytics market. The rise of cloud computing and big data technologies enables pharmaceutical companies to process vast amounts of data efficiently. In North America, the market for cloud-based analytics solutions is expected to reach $5 billion by 2026, indicating a robust demand for innovative data management tools. These technologies facilitate real-time data analysis, allowing companies to make informed decisions quickly. Consequently, the commercial pharmaceutical-analytics market is likely to experience accelerated growth as organizations adopt these advanced data management solutions to enhance their analytical capabilities.

## Future Outlook

The commercial pharmaceutical-analytics market is projected to grow at a 19.1% CAGR from 2025 to 2035, driven by technological advancements and increasing demand for data-driven insights.

**New opportunities:**

- Integration of AI-driven predictive analytics tools for drug development.
- Expansion of real-time data analytics platforms for clinical trials.
- Development of personalized medicine analytics solutions to enhance patient outcomes.

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic investments.

## Segment Insights

### By Application: Hospital (Largest) vs. Home Care (Fastest-Growing)

In the North America bedsores pressure sores market, hospitals are currently the largest segment, holding a significant share due to the high prevalence of bedsores among hospitalized patients. Home care has emerged as a rapidly expanding sector, driven by the increasing preference for at-home treatment and rehabilitation. This growth reflects a shift towards personalized care and cost-effective solutions for managing bedsores outside institutional settings. Long-term care facilities and rehabilitation centers also play crucial roles, but they are growing at a slower pace comparatively.

Hospital (Dominant) vs. Home Care (Emerging)

Hospitals are the dominant force in the North America bedsores pressure sores market, primarily due to their ability to provide specialized care and immediate access to advanced treatment technologies. The infrastructure of hospitals supports comprehensive patient management, ensuring effective monitoring and intervention for bedsores. On the other hand, the home care segment is emerging rapidly, emphasizing the trend towards patient-centric approaches, where comfort and convenience play integral roles. Home care offers personalized solutions that cater to individual needs, making it an attractive option for patients seeking to manage their conditions in a familiar environment. This evolution highlights the need for innovative products and services in both segments to meet their respective demands.

### By Type of Pressure Sore: Stage II (Largest) vs. Stage IV (Fastest-Growing)

In the North America bedsores pressure sores market, Stage II pressure sores hold the largest market share, owing to their prevalence among patients with limited mobility and the necessity for timely intervention. Stage I and Stage III sores also contribute significantly to market dynamics, but Stage II’s combination of risk factors and treatment requirements positions it as the most substantial segment in this category.
As care protocols evolve and awareness of pressure sore prevention becomes more widespread, the growth rate for Stage IV sores is rapidly increasing. These deep tissue injuries necessitate advanced treatment options and long-term care, making them vital in discussions about patient management and health care strategies. The focus on improving outcomes for these severe cases drives market growth and innovation in treatment solutions.

Stage II (Dominant) vs. Stage IV (Emerging)

Stage II pressure sores are characterized by partial-thickness skin loss, which often leads to significant patient discomfort and requires prompt attention. This segment remains predominant due to the high incidence rates in healthcare facilities and the necessity for preventive measures. On the other hand, Stage IV pressure sores, which are full-thickness injuries involving extensive damage to both skin and underlying tissues, are an emerging segment. They reflect a critical area of focus for healthcare providers, as their treatment requires aggressive interventions and a multidisciplinary approach. The rising recognition of the complexities involved in managing Stage IV sores indicates growing investment in research and product development, which in turn enhances the overall market landscape.

### By Treatment Method: Dressings (Largest) vs. Topical Agents (Fastest-Growing)

In the North America bedsores pressure sores market, the treatment methods segment reveals a clear preference among healthcare providers, with dressings emerging as the largest contributor due to their ease of application and effectiveness in wound management. Topical agents, on the other hand, are rapidly gaining traction, demonstrating a significant rise in adoption rates as practitioners seek more advanced solutions for patient care.

Dressings (Dominant) vs. Topical Agents (Emerging)

Dressings play a dominant role in the treatment of bedsores as they are essential for protecting wounds and supporting healing. Their diverse range includes hydrocolloids, foams, and alginates, offering flexibility for various wound conditions. Meanwhile, topical agents represent an emerging category, characterized by formulations that include antimicrobials, growth factors, and enzymes. As healthcare facilities continue to prioritize infection prevention and enhance wound healing, the usage of topical agents is expected to surge, driven by innovations in product formulation and increasing awareness among clinicians.

### By Components: Software (Largest) vs. Services (Fastest-Growing)

In the North America commercial pharmaceutical-analytics market, the segment values of software and services showcase a notable disparity in their market share distribution. Software holds the largest share, benefiting from increased adoption among pharmaceutical companies seeking to streamline their operations and enhance data analytics capabilities. In contrast, services are rapidly gaining traction, driven by the growing demand for customization and integration, which are vital for effective analytics usage.

Growth trends in this segment are shaped significantly by technological advancements and the pressing need for regulatory compliance among pharmaceutical firms. While software solutions are being optimized for better user experience and functionality, the services sector is evolving, with providers focusing on innovative delivery methods and specialized offerings, making it the fastest-growing component within the market. This dynamic interaction between software and services underscores the importance of adaptability in the competitive landscape.

Software (Dominant) vs. Services (Emerging)

Software is recognized as the dominant force in the North America commercial pharmaceutical-analytics market, characterized by robust functionalities and ease of integration within existing infrastructures. It empowers pharmaceutical firms to manage vast amounts of data efficiently, providing insights that drive strategic decision-making. Meanwhile, services are emerging as a critical component, characterized by tailored support, implementation expertise, and ongoing training for users. This segment is increasingly sought after as companies recognize the value of leveraging external expertise to maximize the benefits of their analytics investments. As the market continues to evolve, the interplay between software and services reveals a trend toward comprehensive solutions that blend technology with specialized support to meet the unique needs of the pharmaceutical industry.

## Regional Market Share Analysis

### US : Leading Market with Robust Growth

The US pharmaceutical-analytics market holds a commanding share of 8.1% in North America, driven by increasing healthcare expenditures and a growing emphasis on data-driven decision-making. Key growth drivers include advancements in technology, rising demand for personalized medicine, and supportive government initiatives aimed at enhancing healthcare outcomes. Regulatory policies, such as the 21st Century Cures Act, promote innovation and streamline drug approval processes, further fueling market expansion. Additionally, significant investments in healthcare infrastructure bolster the analytics landscape.

### Canada : Strategic Developments in Healthcare Analytics

Canada's pharmaceutical-analytics market, valued at 1.4%, is on an upward trajectory, supported by increasing healthcare investments and a focus on improving patient outcomes. Key growth drivers include the integration of advanced analytics in healthcare systems and government initiatives aimed at enhancing data accessibility. The Canadian government has implemented policies to support digital health transformation, which is crucial for analytics adoption. The demand for real-time data analytics is rising, particularly in urban centers like Toronto and Vancouver, where healthcare innovation is prioritized.

## Competitive Benchmarking

The commercial pharmaceutical-analytics market in North America is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing demand for data-driven decision-making in healthcare. Key players such as IQVIA (US), Cerner Corporation (US), and Optum (US) are at the forefront, leveraging their extensive data repositories and analytics capabilities to enhance patient outcomes and streamline operations. These companies are strategically positioned to capitalize on the growing emphasis on personalized medicine and real-time analytics, which are reshaping the market's competitive dynamics.In terms of business tactics, companies are increasingly localizing their operations and optimizing supply chains to enhance efficiency and responsiveness. The market appears moderately fragmented, with several players vying for market share, yet the collective influence of major companies like McKesson Corporation (US) and Roche Diagnostics (CH) is significant. Their operational focus on partnerships and technological integration is likely to drive further consolidation and innovation within the sector.

In October  IQVIA (US) announced a strategic partnership with a leading telehealth provider to enhance its analytics capabilities in remote patient monitoring. This collaboration is expected to integrate advanced analytics into telehealth services, thereby improving patient engagement and outcomes. The strategic importance of this move lies in its potential to position IQVIA as a leader in the rapidly evolving telehealth landscape, where data analytics plays a crucial role in patient management.

In September  Cerner Corporation (US) launched a new cloud-based analytics platform aimed at improving interoperability among healthcare systems. This initiative is significant as it addresses the ongoing challenges of data silos in healthcare, enabling providers to access comprehensive patient data seamlessly. By enhancing interoperability, Cerner is likely to strengthen its market position and foster greater collaboration among healthcare stakeholders.

In August  Optum (US) expanded its analytics services through the acquisition of a data science firm specializing in artificial intelligence. This acquisition is pivotal as it enhances Optum's capabilities in predictive analytics, allowing for more accurate forecasting of patient needs and resource allocation. The integration of AI into their analytics framework could provide Optum with a competitive edge in delivering personalized healthcare solutions.

As of November  the competitive trends in the commercial pharmaceutical-analytics market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing service delivery. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and the ability to deliver personalized healthcare solutions. This shift underscores the importance of agility and adaptability in a rapidly changing market environment.

## Report Scope

| MARKET SIZE 2024 | 9.5(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 11.31(USD Billion) |
| MARKET SIZE 2035 | 65.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 19.1% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | IQVIA (US), Cerner Corporation (US), Optum (US), McKesson Corporation (US), Roche Diagnostics (CH), Abbott Laboratories (US), Siemens Healthineers (DE), Philips Healthcare (NL) |
| Segments Covered | Type, Application, Deployment, Components |
| Key Market Opportunities | Integration of artificial intelligence in drug development enhances efficiency in the commercial pharmaceutical-analytics market. |
| Key Market Dynamics | Rising demand for data-driven insights drives innovation in the commercial pharmaceutical-analytics market. |
| Countries Covered | US, Canada |

## Frequently Asked Questions

**Q: What is the current valuation of the North America bedsores pressure sores market?**
A: The market valuation was 9.31 USD Billion in 2024.

**Q: What is the projected market size for the North America bedsores pressure sores market by 2035?**
A: The market is projected to reach 63.35 USD Billion by 2035.

**Q: What is the expected CAGR for the North America bedsores pressure sores market during the forecast period 2025 - 2035?**
A: The expected CAGR is 19.04% during the forecast period 2025 - 2035.

**Q: Which segments are included in the North America bedsores pressure sores market?**
A: The market segments include Hospital, Home Care, Long-term Care Facilities, and Rehabilitation Centers.

**Q: What were the valuations for the Hospital segment in 2024?**
A: The Hospital segment was valued at 3.72 USD Billion in 2024.

**Q: How does the valuation of Stage II pressure sores compare to other stages in 2024?**
A: Stage II pressure sores had a valuation of 2.79 USD Billion, which was the highest among all stages.

**Q: What treatment methods are included in the North America bedsores pressure sores market?**
A: Treatment methods include Dressings, Topical Agents, Surgical Interventions, and Support Surfaces.

**Q: What was the valuation of Support Surfaces in 2024?**
A: Support Surfaces were valued at 2.57 USD Billion in 2024.

**Q: Which companies are considered key players in the North America bedsores pressure sores market?**
A: Key players include Hill-Rom Holdings Inc, Stryker Corporation, and Medtronic plc, among others.

**Q: What is the projected growth trend for the Home Care segment by 2035?**
A: The Home Care segment is expected to grow from 2.79 USD Billion in 2024 to a significantly higher valuation by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/north-america-bedsores-pressure-sores-market-734*